Alnylam Vutrisiran Improved Measures of Heart Structure, Function in ATTR-CM

 − Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile –

− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters –

– In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo –

– Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease –

https://markets.financialcontent.com/wral/article/bizwire-2025-11-8-new-post-hoc-analysis-from-the-helios-b-phase-3-study-shows-vutrisiran-improved-measures-of-heart-structure-and-function-in-patients-with-attr-cm